A Study Evaluating Sotorasib Platinum Doublet Combination Versus

CodeBreaK 202 tests sotorasib + platinum doublet vs pembro + platinum doublet in 1L KRAS G12C NSCLC with PD-L1 <50%. Sotorasib monotherapy showed modest activity (CodeBreaK 200 beat docetaxel on PFS but missed OS). Beating pembro+chemo (established SOC) on PFS is a high bar; prior KRAS G12C + chemo combos lacked immunotherapy comparator wins. Hepatotoxicity concerns with sotorasib+IO exist but this arm avoids IO. Modest downside tilt; primary completion still ~1.4 yrs away adds disclosure risk.

A rigorous BICR-assessed PFS endpoint and randomized Phase 3 design support interpretability, but the experimental regimen must outperform an active pembrolizumab-chemotherapy control. Co-primary PFS/OS ambitions, advanced disease heterogeneity, ongoing recruitment, and substantial time to completion create efficacy and execution risk.

Sotorasib plus platinum chemotherapy has a credible mechanistic and early-clinical efficacy rationale in KRAS G12C NSCLC, where chemo-immunotherapy outcomes can be heterogeneous. BICR PFS is a robust endpoint, but the active pembrolizumab-doublet control, frontline setting, toxicity, and unproven phase 3 durability leave substantial execution risk.

Phase 3 and BICR-assessed RECIST PFS provide a strong readout, but the trial is still recruiting with primary completion in February 2028 and offers no supportive efficacy data. Pembrolizumab plus chemotherapy is an established frontline comparator, so superiority of sotorasib remains uncertain.

Phase 3 head-to-head vs pembro+chemo SOC in first-line nonsquamous NSCLC; sotorasib KRAS G12C targeted but trial design lacks prior first-line PFS data vs this benchmark, endpoint quality high (BICR PFS) but execution over 2.5y and disclosure risk add uncertainty.

CodeBreaK 202 compares sotorasib+chemo to pembro+chemo in 1L KRAS G12C NSCLC. It smartly restricts enrollment to PD-L1 negative patients, where pembro+chemo typically yields a modest ~6.2-month PFS (KN-189). Phase 1b data for sotorasib+chemo in this subgroup showed a strong ~11.9-month PFS. With a large sample size (n=750), the trial is highly powered to detect a statistically significant PFS benefit, making a positive result likely.

Phase 3 head-to-head vs pembrolizumab+chemo in 1L NSCLC is a high bar. Sotorasib's 2L PFS benefit was modest (HR 0.66) and durability limited. Biomarker selection (KRAS G12C) may help, but chemo combo must beat a proven standard. Probability of superiority on PFS is below even odds.

Phase 3 head-to-head vs pembro+platinum doublet, a strong first-line NSCLC standard. Sotorasib has shown activity in KRAS G12C pretreated patients, but beating an IO+chemo backbone on PFS is a high bar. KRAS G12C population may favor targeted therapy, but pembro+chemo efficacy in this subgroup is still meaningful. Trial is early (recruiting, 554 days to completion), adding uncertainty. Historical Phase 3 oncology success vs active comparator is modest.

CodeBreaK 202 tests sotorasib+chemo vs pembrolizumab+chemo in KRAS G12C NSCLC. Sotorasib has strong Phase 2 data (CodeBreaK 100). However, beating immuno-chemo (standard of care) in first-line is difficult. KRAS G12C is a small subset; statistical power and heterogeneity are risks. Modest edge for YES based on targeted efficacy, but high uncertainty remains.

Sotorasib showed PFS benefit in KRAS G12C NSCLC after prior therapy, but its front‑line use with platinum chemo is unproven. Pembrolizumab‑chemo is an established standard with solid PFS data. The Phase 3 trial is still recruiting, so efficacy and safety of the sotorasib doublet remain uncertain, suggesting a slightly sub‑50% chance of a positive PFS result.

Sotorasib (KRAS G12C inhibitor) plus chemo vs pembrolizumab plus chemo in 1L NSCLC. Pembrolizumab-chemo is established standard of care with proven PFS benefit. Sotorasib monotherapy showed modest benefit in pretreated KRAS G12C NSCLC; combining with chemo in 1L is unproven. No prior positive Phase 3 data for this combination. Long timeline (554 days) adds execution risk. Market asks only PFS, not OS—PFS is easier to hit but control arm is strong. Amgen's track record is solid but this is a challenging comparator.

CodeBreaK 202 tests sotorasib+chemo vs pembrolizumab+chemo in 1L nonsquamous NSCLC (likely KRAS G12C+ subset). Pembrolizumab+chemo (KEYNOTE-189) is a strong control with proven OS/PFS benefit. Prior CodeBreaK 200 (sotorasib vs docetaxel 2L) failed to improve OS, raising doubts about sotorasib competitiveness. Sotorasib combos also showed hepatotoxicity signals. Front-line chemo combo may help, but beating a pembro-chemo backbone in KRAS G12C patients is a high bar. PFS win probability below 50%.